Walleye Capital
MCRB icon

Walleye Capital’s Seres Therapeutics MCRB Stock Holding History

Walleye Capital’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,997
Closed -$55.9K – 5683
2023
Q4 		$55.9K Sell
1,997
-3,091
-61% -$81.2K ﹤0.01% 4263
2023
Q3 		$242K Buy
+5,088
New +$388K ﹤0.01% 3402
2023
Q2 		– Sell
-18,116
Closed -$2.05M – 4649
2023
Q1 		$2.05M Buy
18,116
+17,708
+4,340% +$1.92M 0.03% 707
2022
Q4 		$45.7K Buy
+408
New +$54.7K ﹤0.01% 2539
2022
Q3 		– Sell
-4,998
Closed -$343K – 3410
2022
Q2 		$343K Buy
+4,998
New +$431K 0.01% 1231
2021
Q4 		– Sell
-10,883
Closed -$1.51K – 2229
2021
Q3 		$1.51K Buy
+10,883
New +$2.13M 0.04% 299
2019
Q3 		– Sell
-1,414
Closed -$91K – 2104
2019
Q2 		$91K Buy
+1,414
New +$134K 0.01% 1251

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Walleye Capital's MCRB Position: Q1 2024 in Review

Walleye Capital sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 1,997 shares — an estimated $55.9K sold.

Walleye Capital first reported a position in MCRB in Q2 2019 and held it in 7 quarters. The position peaked at $2.05M in Q1 2023. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Walleye Capital reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 1,997 Seres Therapeutics shares in Q1 2024, an estimated $55.9K.
  • Walleye Capital first reported a position in Seres Therapeutics in Q2 2019 and held it in 7 quarters.
  • Walleye Capital's Seres Therapeutics position peaked at $2.05M in Q1 2023.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.